NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Forecast & News

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.11. View Rocket Pharmaceuticals' Earnings History.

Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Rocket Pharmaceuticals.

8 equities research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' shares. Their forecasts range from $27.00 to $42.00. On average, they expect Rocket Pharmaceuticals' share price to reach $35.80 in the next year. This suggests a possible upside of 59.6% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals.

News stories about RCKT stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Rocket Pharmaceuticals.

Some companies that are related to Rocket Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), Allakos (ALLK), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), Home Depot (HD), Cisco Systems (CSCO), Fate Therapeutics (FATE), MEI Pharma (MEIP), NVIDIA (NVDA) and Viking Therapeutics (VKTX).

Rocket Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.10%) and Lindbrook Capital LLC (0.00%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View Institutional Ownership Trends for Rocket Pharmaceuticals.

RCKT stock was sold by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC. View Insider Buying and Selling for Rocket Pharmaceuticals.

RCKT stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel and Rtw Investments, Lp. View Insider Buying and Selling for Rocket Pharmaceuticals.

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCKT stock can currently be purchased for approximately $22.43.

Rocket Pharmaceuticals has a market capitalization of $1.13 billion. The biotechnology company earns $-74,520,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.View Additional Information About Rocket Pharmaceuticals.

The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com/.

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]